2.32
전일 마감가:
$2.37
열려 있는:
$2.36
하루 거래량:
531.02K
Relative Volume:
0.13
시가총액:
$129.71M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
232.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
-12.12%
1개월 성능:
-23.18%
6개월 성능:
+159.04%
1년 성능:
+65.71%
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SPRO
Spero Therapeutics Inc
|
2.32 | 147.60M | 76.19M | -1.61M | 28.98M | 0.01 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2021-01-22 | 재확인 | H.C. Wainwright | Buy |
2020-12-16 | 개시 | Berenberg | Buy |
2020-09-29 | 개시 | Evercore ISI | Outperform |
2019-11-05 | 재확인 | H.C. Wainwright | Buy |
2019-09-09 | 개시 | Janney | Buy |
2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
2017-11-27 | 개시 | BofA/Merrill | Neutral |
2017-11-27 | 개시 | Oppenheimer | Outperform |
2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Is Spero Therapeutics Inc. a good long term investmentAccelerated wealth building - Autocar Professional
What analysts say about Spero Therapeutics Inc. stockUnstoppable investment returns - jammulinksnews.com
Spero Therapeutics Inc. Stock Analysis and ForecastPowerful growth strategies - jammulinksnews.com
What drives Spero Therapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
Will Spero Therapeutics Inc. stock benefit from AI tech trendsTrend Based Entry Alerts - Newser
When is the best time to buy Spero Therapeutics Inc. stockFree Real-Time Trading Opportunities - Newser
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price - simplywall.st
What makes Spero Therapeutics Inc. stock price move sharplyMarket Timing Advice - Newser
Why Spero Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser
How Spero Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average – What’s Next? - Defense World
While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership - Yahoo
Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha
Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN
Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN
Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey
Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa
Complicated Urinary Tract Infection Oral Antibiotic Approaches Approval - Vax-Before-Travel
Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN
Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter
Spero Therapeutics Sees Turbulent Stock Movement Post-Recent Announcements - timothysykes.com
Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail
GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com
Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN
Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):